NEW YORK, Dec. 11 - Rosetta Biosoftware said on Tuesday that it has licensed its Rosetta Resolver gene-expression data-analysis system to Aventis Pharmaceuticals.
Financial or research specifics of the agreement were not revealed.
"The Rosetta Resolver system's ability to be networked into a multi-server global solution for our distributed enterprise was important to us," Christoph Brockel, head of Aventis Pharma's informatics group, said in a statement.
Rosetta Biosoftware is based in Kirkland, Wash., and Aventis Pharmaceuticals, of Cambridge, Mass., is the US business of German life sciences group Aventis Pharma.